Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.

Employee Rating

3.4More
TypePublic
HQWilmington, US
Founded1991
Size (employees)1,208 (est)
Websiteincyte.com
Incyte was founded in 1991 and is headquartered in Wilmington, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Incyte

Hervé Hoppenot

Hervé Hoppenot

Chairman, President, and Chief Executive Officer
Jonathan e Dickinson

Jonathan e Dickinson

Senior Vice President, General Manager, Europe
Lothar H Finke

Lothar H Finke

Head of Clinical Development and General Manager, Japan
David W Gryska

David W Gryska

Executive Vice President, Chief Financial Officer
Reid M Huber

Reid M Huber

Executive Vice President, Chief Scientific Officer
Vijay Iyengar

Vijay Iyengar

Executive Vice President, Global Strategy and Corporate Development
Show more

Incyte Office Locations

Incyte has offices in Wilmington, Planegg, Boulogne-Billancourt, Wien and in 6 other locations
Wilmington, (HQ)
1801 Augustine Rd
Wien,
DC Tower 1 7 Donau-City-Straße
Boulogne-Billancourt,
35 ter avenue André Morizet
Planegg,
9 Fraunhoferstraße
Milan,
Via Fabio Filzi 25/A
Amsterdam,
Paasheuvelweg 25
Show all (10)
Report incorrect company information

Incyte Financials and Metrics

Incyte Revenue

Incyte's revenue was reported to be $1.54 b in FY, 2017
USD

Revenue (Q3, 2018)

449.7m

Net income (Q3, 2018)

29.2m

EBIT (Q3, 2018)

31.1m

Market capitalization (4-Dec-2018)

13.9b

Closing stock price (4-Dec-2018)

65.5

Cash (30-Sep-2018)

1.1b
Incyte's current market capitalization is $13.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

354.9m511.5m753.8m1.1b1.5b

Revenue growth, %

44%47%47%

General and administrative expense

110.0m196.6m303.3m366.4m

R&D expense

260.4m479.5m581.9m1.3b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

85.1m89.8m99.6m198.1m159.3m163.0m187.6m263.5m246.3m269.5m384.1m326.4m381.5m382.3m521.5m449.7m

General and administrative expense

26.4m37.0m40.9m39.4m44.9m51.7m47.6m64.6m66.8m75.8m87.2m90.1m91.3m121.5m108.0m96.5m

R&D expense

71.7m75.6m84.7m88.5m118.4m112.4m132.1m156.8m120.3m143.2m408.0m201.8m269.6m303.1m298.1m292.5m

Operating expense total

98.3m112.7m125.8m128.2m166.2m170.4m187.7m227.4m201.7m247.2m517.4m319.2m366.6m449.4m438.3m418.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

471.4m452.3m521.4m652.3m899.5m

Accounts Receivable

35.4m57.9m114.5m148.8m266.3m

Inventories

406.0k20.5m1.8m4.1m6.5m

Current Assets

555.8m699.2m842.4m994.2m1.5b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(83.1m)(48.5m)6.5m104.2m(313.1m)

Depreciation and Amortization

58.4m52.2m

Inventories

(6.6m)(4.1m)98.0k4.0m4.9m

Accounts Payable

5.1m5.4m5.6m43.8m(7.9m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(40.3m)(34.0m)(70.8m)(11.5m)(18.4m)(9.1m)(48.6m)24.0m58.5m95.3m(187.1m)(199.6m)(163.5m)(41.1m)11.3m40.4m

Depreciation and Amortization

23.9m40.9m15.0m27.4m39.3m13.4m26.9m40.7m

Inventories

(6.6m)(506.0k)(517.0k)(2.6m)2.4m(1.0m)(830.0k)752.0k1.7m4.4m790.0k4.5m4.7m1.9m1.9m3.0m

Accounts Payable

4.3m(1.2m)8.1m7.5m26.6m4.7m2.9m1.8m8.9m25.7m10.7m(6.5m)(5.7m)6.4m7.9m27.8m
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Incyte Online and Social Media Presence

Embed Graph
Report incorrect company information

Incyte News and Updates

XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte

EMERYVILLE, Calif., Sept. 21, 2018 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today that for $15.0 million, it has acquired from Agenus (NASDAQ: AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology ant…

Agenus Receives Milestone Payment from Incyte

LEXINGTON, Mass., Sept. 17, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash milestone from Incyte for the initiation of a...

IMV Inc. Announces Q2 2018 Financial Results

HALIFAX, Nova Scotia, Aug. 08, 2018 (GLOBE NEWSWIRE) --  IMV Inc. (Nasdaq:IMV) (TSX:IMV), a clinical stage immuno-oncology corporation, today released its financial and operational results for the three- and six-month period ended June 30, 2018.

Saddled with a black box and low dose, Lilly, Incyte RA drug Olumiant faces uphill fight

The 2 mg dose of Eli Lilly and Incyte's rheumatoid arthritis drug Olumiant picked up an FDA approval after independent experts flagged safety concerns on the 4 mg dose. And with a black-box warning on its label, the new med will face an uphill fight for sales.

Serine/Threonine Protein Kinase Pim 3 Pipeline Review| Companies Involved in Therapeutics Development: Incyte Corp, Jasco Pharmaceuticals, Novartis AG

Serine/Threonine Protein Kinase Pim 3 Pipeline Review| Latest Developments by Type, by End-Users/Application, by Region - Forecast and Business Outlook Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information

Incyte Company Life and Culture

Report incorrect company information

Incyte Frequently Asked Questions

  • When was Incyte founded?

    Incyte was founded in 1991.

  • Who are Incyte key executives?

    Incyte's key executives are Hervé Hoppenot, Jonathan e Dickinson and Lothar H Finke.

  • How many employees does Incyte have?

    Incyte has 1,208 employees.

  • What is Incyte revenue?

    Latest Incyte annual revenue is $1.5 b.

  • What is Incyte revenue per employee?

    Latest Incyte revenue per employee is $1.3 m.

  • Who are Incyte competitors?

    Competitors of Incyte include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

  • Where is Incyte headquarters?

    Incyte headquarters is located at 1801 Augustine Rd, Wilmington.

  • Where are Incyte offices?

    Incyte has offices in Wilmington, Planegg, Boulogne-Billancourt, Wien and in 6 other locations.

  • How many offices does Incyte have?

    Incyte has 10 offices.